Amicus Therapeutics, Inc. (FOLD) Holdings Raised by Wells Fargo & Company MN

Marco Green
January 14, 2018

According to their observations and findings, the stock could provide a high EPS of $-0.23/share and a low EPS of $-0.38/share.

Amicus Therapeutics, Inc. (FOLD): A -2.99% Dop In This Year - But Still Has Room To Grow 37.61%. The company trades on average around 226000. shares per market session. About 9,448 shares traded. Finally, Vanguard Group Inc. raised its holdings in Amicus Therapeutics by 5.0% in the second quarter. It has underperformed by 4.25% the S&P500.

John Brennan increased its stake in Netapp Inc (NTAP) by 3.31% based on its latest 2017Q3 regulatory filing with the SEC. The Blume Capital Management Inc holds 110,966 shares with $3.78M value, up from 246 last quarter. (FOLD) most recent 13F filing, the company has 56 new institutional holders - accounting for 9.89 million shares of its common stock. Hbk Investments LP who had been investing in Crh Plc for a number of months, seems to be bullish on the $30.94B market cap company. About 1.18M shares traded or 87.97% up from the average. The Boeing Company (NYSE:BA) has risen 41.13% since January 13, 2017 and is uptrending. It has outperformed by 24.43% the S&P500.

Tourbillon Capital Partners Lp decreased Leidos Hldgs Inc (NYSE:LDOS) stake by 612,000 shares to 501,429 valued at $29.70M in 2017Q3. The stock uncovered monthly dynamic performance with growing progress of 10.20%. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. Cognex Corporation had 35 analyst reports since August 4, 2015 according to SRatingsIntel. (NASDAQ:FOLD) for 11,117 shares. Jefferies initiated it with "Buy" rating and $36.0 target in Wednesday, September 27 report. On Wednesday, April 6 the stock rating was upgraded by JP Morgan to "Overweight". The firm has "Neutral" rating by Dundee Securities given on Friday, August 12. The rating was maintained by Canaccord Genuity on Tuesday, October 31 with "Hold".

Investors sentiment increased to 0.83 in Q3 2017. Its down 0.28, from 1.33 in 2017Q2. It improved, as 11 investors sold CRH shares while 43 reduced holdings. Temasek (Private) Ltd reported 15,660 shares. Following the completion of the sale, the insider now directly owns 69,184 shares in the company, valued at $1,017,696.64. Ingalls & Snyder Llc, a New York-based fund reported 47,116 shares. 1St Source Bank & Trust holds 30,478 shares or 0.09% of its portfolio. San Francisco Sentry Invest Gp (Ca) invested 0% of its portfolio in CRH plc (NYSE:CRH). Andra Ap invested 0.23% in The Boeing Company (NYSE:BA). Thomas White Ltd invested in 0.7% or 105,625 shares.

Tradewinds Capital Management Llc, which manages about $444.11 million and $195.93 million US Long portfolio, decreased its stake in Spdr Index Shs Fds (QGBR) by 172,100 shares to 17,845 shares, valued at $947,000 in 2017Q3, according to the filing. 10,888 are held by Sg Americas Secs Ltd Company. Iguana Ltd Liability invested in 60,000 shares. Pnc Fincl Svcs Grp Inc Inc stated it has 201,118 shares. Fifth Third Bancshares invested 0% of its portfolio in CRH plc (NYSE:CRH).

Amicus Therapeutics (NASDAQ:FOLD)'s stock had its "buy" rating reaffirmed by investment analysts at Cowen in a research report issued on Wednesday.

For the current quarter, 6 analysts are projecting a mean EPS of $-0.29/share. Therefore 89% are positive. Amicus Therapeutics has an average rating of "Buy" and a consensus price target of $18.31. Robert W. Baird reissued an "outperform" rating and set a $16.00 price target on shares of Amicus Therapeutics in a report on Monday, September 25th. The firm has "Buy" rating given on Wednesday, May 18 by Bank of America. The rating was maintained by Leerink Swann with "Buy" on Monday, August 31. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD). 365,000 are owned by Ardsley Advisory. The rating was maintained by Cowen & Co on Sunday, June 25 with "Buy". The rating was downgraded by Zacks to "Buy" on Tuesday, August 18. The rating was maintained by Leerink Swann on Monday, October 5 with "Outperform".

Investors sentiment increased to 2.33 in Q3 2017. Its up 0.09, from 1.01 in 2017Q2. Of those transactions, there were 1.82 million shares of FOLD bought and 1.08 million shares sold. 165 funds opened positions while 367 raised stakes. Envestnet Asset Mngmt reported 1,939 shares stake. Of those insider trades, 278,670 shares of Amicus Therapeutics, Inc. were purchased and 882,797 shares were sold.

Want to see what other hedge funds are holding FOLD? Finally, BlackRock Advisors LLC raised its stake in Amicus Therapeutics by 6.2% in the second quarter.

WARNING: "Amicus Therapeutics (FOLD) Receives "Buy" Rating from Cowen" was first posted by Week Herald and is the sole property of of Week Herald. (NASDAQ:FOLD) or 1.26 million shares. Exane Derivatives invested in 0.01% or 295 shares. 50,194 Amicus Therapeutics, Inc. Shares for $300,002 were sold by HAYDEN DONALD J JR. Teacher Retirement Of Texas holds 0% or 12,048 shares. American International Group Inc. raised its holdings in Amicus Therapeutics by 23.1% during the third quarter. (NASDAQ:FOLD) for 100,000 shares. Pacad Inv Ltd stated it has 0.11% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 1.47M shares. Hudson Bay Mngmt Limited Partnership holds 0.04% of its portfolio in Amicus Therapeutics, Inc. Florida-based State Board Of Administration Of Florida Retirement System has invested 0% in Amicus Therapeutics, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER